Navigation Links
TNFerade(TM) Phase III Data Presented at ASCO
Date:6/1/2009

" then "Webcasts & Data" then "Data Presentations."

About PACT

GenVec's PACT trial is a multi-center, randomized, active, and controlled study of 330 patients designed to evaluate the safety and efficacy of TNFerade plus standard of care versus standard of care alone in patients with locally advanced pancreatic cancer. The next interim analysis is expected to occur after two-thirds of the events (or 184 deaths) have occurred in the trial. Results are expected to be announced in early 2010.

About TNFerade(TM)

TNFerade, which has not yet been approved for use, is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF alpha in the tumor. TNFerade has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
4. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
11. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014   Surefire Medical , Inc., the developer ... maximize targeted delivery of embolization agents in minimally invasive ... John R. Daniels , MD of the University ... oncologist Steven C. Katz , MD of the ... Advisory Board (SAB).    "The role of ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... leader in the development, assembly, marketing and sale of ... announced that it will participate in the Arab Health ... 24-27, 2011 at the Dubai World Trade Centre in ...
... Calif., Jan. 11, 2011 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today the first published five-year outcomes on ... CyberKnife® Robotic Radiosurgery System . The multi-center study, published ... , found that 93 percent of patients had no recurrence ...
Cached Medicine Technology:Dehaier Medical Announces Participation in Arab Health 2011 2First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 2First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 3First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 4
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 With the Affordable ... national survey by the American Institutes for Research (AIR) finds ... how to use health insurance, but 42 percent say they ... plan’s details before signing up for coverage. , The AIR ... only 20 percent able to calculate correctly how much they ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... tests, but side effects concern researchers , FRIDAY, Jan. ... longer prescribed may find new life as an effective ... as clorgyline, hasn,t been tested in humans as a ... can reduce and even reverse the symptoms of heart ...
... in those who worked out while dieting , THURSDAY, Jan. ... this year, consider adding a regular exercise program while you,re ... outcomes -- such as lower blood pressure and cholesterol levels ... , "It,s better to lose weight with a combination of ...
... sleep nightly, study finds, , FRIDAY, Jan. 8 (HealthDay News) ... teachers of adolescents, a new study finds that most U.S. ... the study found that almost 69 percent of high school ... about 8 percent of teens get the optimal amount -- ...
... messaging from quitline specialists (i.e., stressing the benefits ... those who received standard-care messaging (i.e., potential losses ... a new study published online January 7 in ... . Researchers also established that quitline specialists can ...
... to genetically modify human embryonic stem cells. Their approach, which ... genes, will make possible the rapid development of stem cell ... diseases and as testbeds on which to screen potential treatments, ... whole human embryonic stem cell field. Otherwise, there,s really few ...
... has shown that metformin, a drug often used in the ... patients who have both diabetes and advanced heart failure. The ... by researchers at the David Geffen School of Medicine ... "There may be over two million individuals with heart failure ...
Cached Medicine News:Health News:Older Antidepressant May Treat Heart Failure 2Health News:For Fitness, Cutting Calories May Not Be Enough 2Health News:For Fitness, Cutting Calories May Not Be Enough 3Health News:Two-Thirds of American Teens Need More Shut-Eye 2Health News:Two-Thirds of American Teens Need More Shut-Eye 3Health News:Quitline messages that stress benefits of quitting may improve smoking cessation 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 3Health News:UCLA study shows metformin is safe for patients with advanced heart failure and diabetes mellitus 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: